QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer | Zendy

Hiromi Okuyama | Zendy; Seigo Nakamura | Zendy; Sadako AkashiTanaka | Zendy; Terumasa Sawada | Zendy; Satoko Handa | Zendy; Yasuhisa Kato | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer

Author(s) -

Hiromi Okuyama,

Seigo Nakamura,

Sadako AkashiTanaka,

Terumasa Sawada,

Satoko Handa,

Yasuhisa Kato

Publication year - 2018

Publication title -

meme sağlığı dergisi/meme sağlığı dergisi

Language(s) - English

Resource type - Journals

eISSN - 1306-0953

pISSN - 1306-0945

DOI - 10.5152/ejbh.2018.4174

Subject(s) - medicine , epirubicin , docetaxel , breast cancer , paclitaxel , chemotherapy , cyclophosphamide , quality of life (healthcare) , oncology , stage (stratigraphy) , cancer , gastroenterology , paleontology , nursing , biology

A previous randomized phase II study showed that neoadjuvant nab-paclitaxel (nab-PTX) 100 mg/m 2 ) was effective and well-tolerated in patients with HER2-negative early-stage breast cancer, compared with docetaxel (DTX). We evaluated patient outcomes in terms of the Functional Assessment of Cancer Therapy-Breast (FACT-B), as a measure of health-related quality of life (HRQoL).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research